Germline-targeting immunogens

Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483.

Abstract

In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurable binding to a recombinant gp140 Env protein (derived from the dual-tropic 89.6 virus), which was efficiently recognized by the mature (somatically mutated) antibodies. At that time, a small number of bNAbs were available, but in the following years, the implementation of high-throughput B-cell isolation and sequencing assays and of screening methodologies facilitated the isolation of greater numbers of bNAbs from infected subjects. Using these newest bNAbs, and a wide range of diverse recombinant Envs, we and others confirmed the observations made by Dimitrov's group. The results from these studies created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs and has led to the "germline-targeting" immunization approach. Here we discuss this approach in detail: what has been done so far, the advantages and limitations of the current germline-targeting immunogens and of the animal models used to test them, and we conclude with a few thoughts about future directions in this area of research.

Keywords: HIV; B-cell receptors; Env; germline antibodies; immunogens.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Neutralizing / metabolism*
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / virology
  • HIV Antibodies / metabolism*
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • High-Throughput Screening Assays
  • Humans
  • Protein Binding
  • Vaccination
  • Viral Envelope Proteins / immunology*
  • env Gene Products, Human Immunodeficiency Virus / metabolism*

Substances

  • Antibodies, Neutralizing
  • HIV Antibodies
  • Viral Envelope Proteins
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1